BridgeMD
New treatment option for Obsessive-Compulsive Disorder
Official title Identifying Local Field Potential Biomarkers for Obsessive-compulsive Disorder Treatment With Deep Brain Stimulation
ClinicalTrials.gov ID: NCT06542224
What this study is testing
- What it's testing
- Obsessive-compulsive disorder (OCD) is a complex and severe mental illness characterized by multiple symptoms and is considered a leading cause of non-fatal health loss. However, nearly 20% of patients do not respond to standard pharmacological or psychological treatments.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Diagnosed with OCD according to the criteria in the DSM-5.
- Age between 18 and 65 years.
- Duration of illness of more than 3 years.
- Ineffectiveness of systematic treatment with three types of serotonin reuptake inhibitors (including clomipramine) and augmentation agents, with no...
- Ineffectiveness of CBT treatment or repeated refusal of CBT treatment.
You likely can't join if
- Presence of bipolar disorder, schizoaffective disorder, schizophrenia, or other psychotic disorders.
- Severe personality disorders.
- Severe physical illnesses or organic brain diseases.
- Diagnosis of alcohol or substance abuse and dependence according to DSM-IV criteria within one year prior to screening.
- Study participants with contraindications for surgery, such as major medical comorbidities or inability to discontinue anticoagulant medications.
- Preoperative head MRI showing significant structural abnormalities.
See the full eligibility criteria
- Diagnosed with OCD according to the criteria in the DSM-5.
- Age between 18 and 65 years.
- Duration of illness of more than 3 years.
- Ineffectiveness of systematic treatment with three types of serotonin reuptake inhibitors (including clomipramine) and augmentation agents, with no improvement after continuous high-dose serotonin reuptake inhibitor...
- Ineffectiveness of CBT treatment or repeated refusal of CBT treatment.
- Y-BOCS total score of 25 or higher.
- Significant impairment in social functioning, such as inability to work or attend school, or a noticeable decline in personal life skills.
- No severe impairment in insight, and capable of signing informed consent and surgery consent forms.
- Presence of bipolar disorder, schizoaffective disorder, schizophrenia, or other psychotic disorders.
- Severe personality disorders.
- Severe physical illnesses or organic brain diseases.
- Diagnosis of alcohol or substance abuse and dependence according to DSM-IV criteria within one year prior to screening.
- Study participants with contraindications for surgery, such as major medical comorbidities or inability to discontinue anticoagulant medications.
- Preoperative head MRI showing significant structural abnormalities.
- Contraindications for MRI examination (excluding the DBS implant or stimulator itself).
- Pregnancy or breastfeeding.
- Study participants currently enrolled in another research study unrelated to the current study.
- Any condition that currently or in the future might endanger the safety of the study participant or prevent the successful participation in the study (including family support, medical, psychological, social, or...
The study team makes the final eligibility decision.
Where it's taking place
- Chengdu, Sichuan, China
- Zigong, Sichuan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chengdu, Sichuan, China; Zigong, Sichuan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.